Kilambi News
Sunday, November 22, 2026

Archive

Every story, newest first.

Thursday, November 5, 2026

Rates

Treasury yields fall after refunding keeps sizes steady

US Treasury yields fell across the curve on November 4 after the quarterly refunding statement held auction sizes steady, with the 10 year note down 5.8 basis points to 4.89 percent and the 5 year down 5.4 basis points to 4.69 percent.

Rates

Spain tourist spending rises 8.1 percent in September

International tourists spent 14,488 million euros in Spain in September, up 8.1 percent on a year earlier, taking spending for the first nine months of 2026 to 114,380 million euros, up 8.0 percent.

Rates

Rates also notable: Bank of England decides at noon London

The Bank of England raised Bank Rate to 4.0 percent at noon London time, voting 8 to 1, Banxico surprised with a cut to 6.25 percent, and a $4 billion Treasury buyback runs at 1:40 PM Eastern.

Life Sciences

Kamau shows direct sickle cell mutation correction in three patients

Kamau Therapeutics reported on November 4 that all three patients treated with its revised nula-cel process are transfusion independent with no vaso-occlusive events, with sickle haemoglobin below 20 percent beyond six months.

Life Sciences

Ideaya files first drug application and closes an eye cancer trial

Ideaya Biosciences completed its first new drug application, for darovasertib plus crizotinib in metastatic uveal melanoma, and in the same update closed the Phase 3 OptimUM-010 trial, saving an estimated 100 million to 125 million dollars.

Life Sciences

Former Madrigal executive sues alleging Rezdiffra safety coverup

Madrigal Pharmaceuticals' former head of clinical development has filed a federal whistleblower lawsuit alleging the company censored liver safety data for Rezdiffra and forced him out after he raised concerns, an allegation the reporting stresses is unproven.

Life Sciences

AstraZeneca reportedly offers about 10 billion dollars for Rhythm

AstraZeneca has made a non-binding offer of about 10 billion dollars, up to 134 dollars a share including milestones, for rare obesity drugmaker Rhythm Pharmaceuticals, Reuters reported on November 4, citing three people familiar with the matter.

Life Sciences

Also notable in life sciences: committees, ASH abstracts, Summit date

Democrats taking Senate health committees, the first ASH 2026 abstracts, and a November 14 FDA date for Summit's ivonescimab lead the smaller life sciences items for November 5.

Life Sciences

Alethio raises 90 million dollars for rare blood cancer antibody

Oxford based Alethio Therapeutics closed an oversubscribed 90 million dollar Series A on November 5 to take its G6B targeting antibody ATX-011 into Phase 1/2a studies in essential thrombocythaemia.

Life Sciences

AbbVie licenses Nxera bowel disease candidate for up to 1.47 billion dollars

AbbVie will pay 100 million dollars upfront and up to 1.37 billion dollars in milestones for worldwide rights to Nxera Pharma's oral EP4 agonist NXE0033744 in inflammatory bowel disease, the companies announced on November 4.